UBS Group AG Purchases 244,714 Shares of DBV Technologies S.A. $DBVT

UBS Group AG lifted its position in DBV Technologies S.A. (NASDAQ:DBVT) by 165,347.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 244,862 shares of the company’s stock after acquiring an additional 244,714 shares during the period. UBS Group AG owned 0.61% of DBV Technologies worth $4,694,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. New York State Common Retirement Fund bought a new position in shares of DBV Technologies in the 3rd quarter worth approximately $34,000. GAMMA Investing LLC raised its position in shares of DBV Technologies by 38.4% in the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock worth $51,000 after acquiring an additional 744 shares in the last quarter. Two Sigma Investments LP bought a new position in shares of DBV Technologies in the 3rd quarter worth approximately $167,000. Citadel Advisors LLC bought a new position in shares of DBV Technologies in the 3rd quarter worth approximately $220,000. Finally, DLD Asset Management LP bought a new position in shares of DBV Technologies in the 3rd quarter worth approximately $250,000. Institutional investors own 71.74% of the company’s stock.

DBV Technologies Stock Up 0.2%

DBV Technologies stock opened at $18.57 on Friday. The company has a market capitalization of $1.10 billion, a P/E ratio of -4.16 and a beta of -0.96. The stock’s 50 day moving average is $20.19 and its 200 day moving average is $19.24. DBV Technologies S.A. has a twelve month low of $7.53 and a twelve month high of $26.18.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.42). DBV Technologies had a negative return on equity of 129.88% and a negative net margin of 2,895.37%.The company had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $1.11 million. As a group, equities analysts expect that DBV Technologies S.A. will post -0.47 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on DBVT shares. Guggenheim reissued a “buy” rating and issued a $51.00 target price on shares of DBV Technologies in a research report on Monday, May 4th. Citigroup reissued an “outperform” rating on shares of DBV Technologies in a research report on Friday, May 1st. Wall Street Zen upgraded DBV Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, May 2nd. Finally, Citizens Jmp upped their price target on DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a research note on Friday, May 1st. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.25.

DBV Technologies Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.